Genentech’s Tecentriq and Avastin reduce the risk of disease worsening or death from RCC December 29, 2017Vol.40 No.11
Phase III study of venetoclax in combination with rituximab meets primary endpoint December 29, 2017Vol.40 No.11
Juno Therapeutics and Celgene release additional data from TRANSCEND trial December 29, 2017Vol.40 No.11
Pfizer’s talazoparib extends PFS in phase III trial in metastatic breast cancer December 29, 2017Vol.40 No.11
Conversation with The Cancer LetterFree Lefkofsky: CancerLinQ has value in ushering in an era of precision medicine December 21, 2017Vol.44 No.01By Paul Goldberg
Conversation with The Cancer LetterFree Hudis: ASCO needed collaborators to help CancerLinQ deliver faster on its mission December 21, 2017Vol.44 No.01By Paul Goldberg
Free ASCO forms collaboration with two Big Data firms to grow CancerLinQ December 21, 2017Vol.44 No.01By Paul Goldberg
Free As FDA, AHRQ spar over incidence estimates for uterine sarcomas, FDA reiterates recommendation to restrict power morcellation December 15, 2017Vol.43 No.46By Matthew Bin Han Ong
Five health systems join Strata Oncology network to sequence and match patients to targeted therapy trials December 15, 2017Vol.43 No.46By Matthew Bin Han Ong
